A Phase I/II, Prospective, Open-Label Study to Determine the Safety and Efficacy of CC-4047 in Patients With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis.

Trial Profile

A Phase I/II, Prospective, Open-Label Study to Determine the Safety and Efficacy of CC-4047 in Patients With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2015

At a glance

  • Drugs Pomalidomide (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Jan 2011 Planned end date changed from 1 May 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 28 Jul 2010 Planned end date changed from 1 May 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
    • 27 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top